

Docket No. 248475US0CIP



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Toshiharu OHTA, et al.

SERIAL NO: 10/773,344

GAU: 1646

FILED: February 9, 2004

EXAMINER:

FOR: DIAMINE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon


Daniel R. Evans, Ph.D.

Registration No. 55,868

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 248475US0CIP		SERIAL NO. 10/773,344	
LIST OF REFERENCES CITED BY APPLICANT 				APPLICANT Toshiharu OHTA, et al.			
				FILING DATE February 9, 2004		GROUP 1646	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	TRADEMARK OFFICE	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO						
	AP						
	AQ						
	AR						
	AS						
	AT						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AU	Jan J. Sigma, et al., "THE IDEAL ANTI-THROMBOTIC DRUG," Thrombosis Research, Erratum, Vol. 68, pp. 507-512, 1992.					
	AV	Susan Elodi, et al., "OPTIMIZATION OF CONDITIONS FOR THE CATALYTIC EFFECT OF THE FACTOR IXa - FACTOR VIII COMPLEX: PROBABLE ROLE OF THE COMPLEX IN THE AMPLIFICATION OF BLOOD COAGULATION," Thrombosis Research, Vol. 15, pp. 617-629, 1979.					
	AW	Jerome E. Teitel, et al., "PROTECTION OF FACTOR Xa FROM NEUTRALIZATION BY THE HEPARIN-ANTITHROMBIN COMPLEX," Journal of Clinical Investigation, Vol. 71, pp. 1383-1391, May 1983.					
	AX	Mebio Vol. 14, No. 8, pp. 92-97, with partial English Translation					
	AY	Lloyd Waxman, et al., "TICK ANTICOAGULANT PEPTIDE (TAP) IS A NOVEL INHIBITOR OF BLOOD COAGULATION FACTOR Xa," Science, Vol. 248, pp. 593-596, May 4, 1990.					
	AZ	Elka Nutt, et al., "THE AMINO ACID SEQUENCE OF ANTISTATSIN," The Journal of Biological Chemistry, Vol. 263, pp. 10162-10167, July 25, 1988.				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner							
Date Considered							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							